Detection of tumor-specific marker for minimal residual disease
in multiple myeloma patients

J 2015

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

SEDLAŘÍKOVÁ, Lenka; Lenka BEŠŠE; Fedor KRYUKOV; Jana PELCOVA; Zdeněk ADAM et. al.

Basic information

Original name

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Authors

SEDLAŘÍKOVÁ, Lenka (203 Czech Republic, belonging to the institution); Lenka BEŠŠE (203 Czech Republic, belonging to the institution); Fedor KRYUKOV (643 Russian Federation, belonging to the institution); Jana PELCOVA (203 Czech Republic); Zdeněk ADAM (203 Czech Republic); Luděk POUR (203 Czech Republic); Roman HÁJEK (203 Czech Republic, belonging to the institution) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic, Olomouc, Palacký University, 2015, 1213-8118

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 0.924

RIV identification code

RIV/00216224:14110/15:00080589

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.5507/bp.2014.035

UT WoS

000366566700007

EID Scopus

2-s2.0-84949666318

Keywords in English

multiple myeloma; minimal residual disease; tumor-specific marker; ASO PCR; RQ-PCR; IgH gene rearrangement

Abstract

In the original language

Aim. Multiple myeloma (MM) is a malignant lymphoproliferative disease of terminally differentiated B lymphocytes, characterized by expansion of monoclonal plasma cells. It is the second most common hematological cancer in the world. The introduction of novel drugs is slowly turning MM into a chronic disease. The aim of treatment is hematological remission and eradication of clinical manifestation. Nevertheless, most MM patients eventually relapse. For this reason, research is focused on more accurate monitoring of remission and relapse by molecular biology techniques. One of these techniques is allele-specific PCR and quantitative real-time PCR based on specific detection of VDJ immunoglobulin heavy chain gene rearrangement of clonal cells. The hypervariable region of IgH rearrangement is used as a marker for detection of minimal residual disease (MRD) in MM as this sequence is used for allele-specific primers and probe design. This technique is a complementary tool for flow cytometry in MRD detection in MM. The aim of this study was to introduce detection of MRD by PCR in the Czech Republic. Results. We successfully introduced qualitative and quantitative detection of a tumor marker for MRD assessment of MM by PCR in our laboratory.

Links

GAP304/10/1395, research and development project

Name: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií

Investor: Czech Science Foundation

MSM0021622434, plan (intention)

Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

MUNI/C/0963/2012, interní kód MU

Name: Detekce minimální residuální choroby u mnohočetného myelomu

Investor: Masaryk University, Rector's Program

NT11154, research and development project

Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu

Investor: Ministry of Health of the CR

Cite

SEDLAŘÍKOVÁ, Lenka; Lenka BEŠŠE; Fedor KRYUKOV; Jana PELCOVA; Zdeněk ADAM; Luděk POUR; Roman HÁJEK and Sabina ŠEVČÍKOVÁ. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic. Olomouc: Palacký University, 2015, vol. 159, No 4, p. 554-561. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2014.035.

@article{1188724,
   author = {Sedlaříková, Lenka and Bešše, Lenka and Kryukov, Fedor and Pelcova, Jana and Adam, Zdeněk and Pour, Luděk and Hájek, Roman and Ševčíková, Sabina},
   article_location = {Olomouc},
   article_number = {4},
   doi = {http://dx.doi.org/10.5507/bp.2014.035},
   keywords = {multiple myeloma; minimal residual disease; tumor-specific marker; ASO PCR; RQ-PCR; IgH gene rearrangement},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic},
   note = {http://biomed.papers.upol.cz/},
   title = {Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients},
   volume = {159},
   year = {2015}
}

TY  - JOUR
ID  - 1188724
AU  - Sedlaříková, Lenka - Bešše, Lenka - Kryukov, Fedor - Pelcova, Jana - Adam, Zdeněk - Pour, Luděk - Hájek, Roman - Ševčíková, Sabina
PY  - 2015
TI  - Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients
JF  - Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic
VL  - 159
IS  - 4
SP  - 554-561
EP  - 554-561
PB  - Palacký University
SN  - 12138118
N1  - http://biomed.papers.upol.cz/
KW  - multiple myeloma
KW  - minimal residual disease
KW  - tumor-specific marker
KW  - ASO PCR
KW  - RQ-PCR
KW  - IgH gene rearrangement
N2  - Aim. Multiple myeloma (MM) is a malignant lymphoproliferative disease of terminally differentiated B lymphocytes, characterized by expansion of monoclonal plasma cells. It is the second most common hematological cancer in the world. The introduction of novel drugs is slowly turning MM into a chronic disease. The aim of treatment is hematological remission and eradication of clinical manifestation. Nevertheless, most MM patients eventually relapse. For this reason, research is focused on more accurate monitoring of remission and relapse by molecular biology techniques. One of these techniques is allele-specific PCR and quantitative real-time PCR based on specific detection of VDJ immunoglobulin heavy chain gene rearrangement of clonal cells. The hypervariable region of IgH rearrangement is used as a marker for detection of minimal residual disease (MRD) in MM as this sequence is used for allele-specific primers and probe design. This technique is a complementary tool for flow cytometry in MRD detection in MM. The aim of this study was to introduce detection of MRD by PCR in the Czech Republic. Results. We successfully introduced qualitative and quantitative detection of a tumor marker for MRD assessment of MM by PCR in our laboratory.
ER  -

SEDLAŘÍKOVÁ, Lenka; Lenka BEŠŠE; Fedor KRYUKOV; Jana PELCOVA; Zdeněk ADAM; Luděk POUR; Roman HÁJEK and Sabina ŠEVČÍKOVÁ. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. \textit{Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic}. Olomouc: Palacký University, 2015, vol.~159, No~4, p.~554-561. ISSN~1213-8118. Available from: https://dx.doi.org/10.5507/bp.2014.035.

Přehled o publikaci